A new medication that targets part of the brain’s stress system may help reduce alcohol use in people with alcohol use disorder (AUD), according to a new study. Researchers led by Raye Litten, from US National Institute on Alcohol Abuse and Alcoholism (NIAAA), conducted a randomised clinical trial of a new compound, called ABT-436, designed to block the effects of vasopressin, a neuropeptide produced in the hypothalamus of the brain.
“Vasopressin helps to regulate the pituitary adrenal axis and other brain circuits involved in emotion. As such, it plays a role in regulating stress, anxiety, and their interaction with AUD,” said Litten.
Litten and colleagues recruited 144 alcohol-dependent adult men and women for the 12-week study. During a 28-day baseline period, female participants consumed at least 28 drinks per week, while male participants consumed at least 35 drinks per week. Participants were then randomised to receive either placebo tablets or ones containing the ABT-436 compound.
- Ae Dil Hai Mushkil Audience Reaction: Ranbir, Aishwarya, Anushka Starrer Gets A Thumbs Up
- Bigg Boss 10, October 27 Review: Navin, Lokesh Fights During The Immunity Task
- Shivaay Audience Reaction: Ajay Devgn Impresses Viewers
- Pakistan High Commission Staffer Caught With Defence Documents: What It Means For India & Pakistan
- The Royal Opera House Reopens After Decades Of Neglect: Here’s A Quick Tour
- Tata Sons Rubbishes Cyrus Mistry’s Allegations: Here’s What Happened
- Pakistan High Commissioner denies allegations leveled on his staffer for espionage activities
- Odisha: Villagers Refuse To Cremate Dalit Woman’s Body
- Here’s What Farhan Akhtar Said On Karan Johar-MNS ‘Deal’ Over Ae Dil Hai Mushkil’s Release
- Government’s Diwali Gift to Central Government Employees, Pensioners
- Bigg Boss 10 26th October Review: This Episode Is All About Fights
- New Zealand Beat India By 19 Runs In Ranchi; Series Levelled At 2-2
- DND Toll-Free: Noida Toll Company Moves Supreme Court Against Allahabad High Court
- British PM Theresa May Says Kashmir Is A Matter For India, Pakistan To Sort Out
- J&K: Students Suffer As Schools Along LOC Forced To Shut Amid Firing
Researchers monitored participants’ alcohol consumption, as well as their mood changes and smoking habits, as these are known to co-vary with alcohol consumption. They found that participants receiving ABT-436 experienced more days of alcohol abstinence than those receiving the placebo. In particular, participants who reported high levels of stress appeared to respond better to ABT-436, in that both the frequency of their drinking and the number of heavy drinking days they experienced decreased.
“Our findings suggest that potential future studies with drugs targeting vasopressin blockade should focus on populations of people with AUD who also report high levels of stress,” said first author Megan Ryan, a clinical project manager in the NIAAA Division of Medications Development.
Smokers may be another population that could benefit from ABT-436. In addition to its effects on alcohol consumption, study participants receiving the new compound experienced a reduction in smoking, researchers said. They suspect that ABT-436 might be targeting the same areas in the brain that relate to withdrawal and stress, and, in the process, influencing both tobacco and alcohol use disorders. The research was published in the journal Neuropsychopharmacology.